Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1049 in Advanced Solid Tumors
NCT07380334Phase 1Recruiting
- Sponsor
- Hengrui
- Start
- Mar 2026
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of SHR-1049 in solid tumor (6 arms), sponsored by Hengrui. Primary endpoints: Dose-Limiting Toxicity at 1 year, Adverse Events at 12 months and 3 more. Started Mar 2026; status: recruiting.
02
Drugs
SHR-1049
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07380334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07380334.